Sameem Abedin

Dr. Sameem Abedin is an Associate Professor in the Department of Medicine, Division of Hematology and Oncology at the Medical College of Wisconsin. He serves as Medical Director of the Inpatient Translational Research Unit and previously directed the Adult Early Phase Program in Hematologic Malignancies. Dr. Abedin completed his medical training at Sidney Kimmel Medical College, residency at the University of Pittsburgh, and fellowship in Hematology/Oncology at Northwestern University.

Dr. Abedin's research focuses on acute myeloid leukemia therapeutics and graft-versus-host disease management. His laboratory work investigates novel therapeutic approaches for relapsed/refractory AML, including CDK9 inhibitors and antibody-drug conjugates, while his clinical research examines GVHD prophylaxis strategies and transplantation outcomes. His recent publications demonstrate expertise in translating laboratory findings to clinical applications for hematologic malignancy patients.

Analysis of Dr. Abedin's 15 most recent publications (2024-2025) reveals a strong focus on therapeutic innovation in AML and GVHD management. His work spans from early-phase clinical trials of novel agents to comparative effectiveness research and practice-changing supportive care strategies. The publications demonstrate methodological diversity including randomized trials, cohort studies, and systematic reviews across high-impact hematology journals.

• Hobart Amory Hare Medical Honor Society (2008-2009)
• Foerderer Award for International Study (2009)
• ASBMT Clinical Research Scholar (2016)
• CTSI Clinical Research Scholar (2017-2019)
• Faculty Development Award, Medical College of Wisconsin (2018-2019)
• Top Patient Experience Award, Froedtert Hospital (2019)

Dr. Abedin actively mentors medical students, residents, and fellows, with several mentees presenting at national meetings and publishing in peer-reviewed journals. His research program is supported by multiple industry-sponsored clinical trials where he serves as Principal Investigator, including studies of Lintuzumab-Ac225 for AML and Neihulizumab for GVHD. As Medical Director of the Inpatient Translational Research Unit, he oversees the infrastructure for early-phase clinical trials requiring coordinated inpatient care, facilitating the rapid growth of the institution's clinical trial portfolio.